218898-24-9

Upstream product

• 19131-21-6 (2S)-pentane-1,2,5-triol 
• 2186-92-7 p-Anisaldehyde dimethyl acetal 
• 603040-45-5 C₁₃H₁₆O₃ 
• 196080-40-7 methyl (4S)‐4,5‐dihydroxypentanoate 
• 55094-97-8 (S)-dimethyl 2-hydroxypentanedioate 
• 218898-23-8 3-[(S)-2-(4-Methoxy-phenyl)-[1,3]dioxolan-4-yl]-propionic acid methyl ester 

Downstream Products

• 218898-25-0 3-[(S)-2-(4-Methoxy-phenyl)-[1,3]dioxolan-4-yl]-propionaldehyde 
• 603040-47-7 (S)-(+)-5-(tert-butyldimethylsiloxy)-2-(p-methoxybenzyloxy)-1-pentanol 
• 603040-48-8 (2S)-5-tert-butyldimethylsilyloxy-2-(p-methoxybenzyloxy)pentanal 
• 603040-46-6 (4S)-4-(1'-tert-butyldimethylsiloxypropane-3'-yl)-2-(p-methoxyphenyl)-1,3-dioxolane 
• 218898-37-4 tert-Butyl-[(E)-(S)-7-{(4S,5S)-2,2-dimethyl-5-[(E)-2-((S)-4-methyl-3,6-dihydro-2H-pyran-2-yl)-vinyl]-[1,3]dioxolan-4-yl}-4-(4-methoxy-benzyloxy)-2-methylene-hept-5-enyloxy]-diphenyl-silane 
• 218898-29-4 (S)-4-(tert-Butyl-diphenyl-silanyloxymethyl)-2-(4-methoxy-benzyloxy)-pent-4-enal 
• 218898-27-2 tert-Butyl-{2-[(S)-2-(4-methoxy-phenyl)-[1,3]dioxolan-4-ylmethyl]-allyloxy}-diphenyl-silane 
• 218898-28-3 (S)-4-(tert-Butyl-diphenyl-silanyloxymethyl)-2-(4-methoxy-benzyloxy)-pent-4-en-1-ol 
• 218898-26-1 2-[(S)-2-(4-Methoxy-phenyl)-[1,3]dioxolan-4-ylmethyl]-propenal 
• 218898-39-6 2-[(S)-2-(4-Methoxy-phenyl)-[1,3]dioxolan-4-ylmethyl]-prop-2-en-1-ol 

Relevant academic research and scientific papers

Total Synthesis of Cytospolide D and Its Biomimetic Conversion to Cytospolides M, O, and Q

A total synthesis of cytospolide D, starting from l-glutamic acid, is described. The critical macrolactonization to the 10-membered lactone containing an (E)-configured double bond was successfully achieved by Shiina esterification. Conversion of cytospol

MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS

The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R1 -R11, t, X, Y, Z, and n are as defined herein.

Synthetic approaches towards laulimalide: Synthesis of the C12-C29 fragment

A synthesis of the C12-C29 fragment of laulimalide 1 is described. This synthesis involves the Julia trans-olefination as a key step.